

Journalbeiträge

1. Alt-Epping B, Wulf G, Nauck F (2011) Palliative care for patients with hematological malignancies-a case series. *ANN HEMATOL*, 90: 613-5.
2. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinlage T, Menck K, Hupfeld T, Koch R, Trümper L, Wulf GG (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. *P NATL ACAD SCI USA*, 108: 15336-41.
3. Borchmann P, Gökbüget N, Wulf G, Trümper L (2011) [Lymphatic neoplasias in young patients]. *ONKOLOGIE*, 34 Suppl 5: 6-11.
4. Bräulke F, Schanz J, Steffens R, Liehr T, Manvelyan M, Chudoba I, Haase D (2011) Two different del(5q) clones in a patient with myelodysplastic syndrome. *LEUKEMIA LYMPHOMA*, 52: 1811-4.
5. Brembeck FH, Wiese M, Zatulana N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W (2011) BCL9-2 promotes early stages of intestinal tumor progression. *GASTROENTEROLOGY*, 141: 1359-70, 1370.e1-3.
6. Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG (2011) Multikinase inhibitor sorafenib exerts cytotoxic efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. *BRIT J HAEMATOL*, 152: 401-12.
7. Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K, Wolff HA, Rothe H, Middel P, Becker H, Ghadimi MB, Beissbarth T, Liersch T (2011) Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. *ANN SURG ONCOL*, 18: 2442-52.
8. Dohm A, Hasenkamp J, Bertsch HP, Maas JH, Truemper L, Wulf G (2011) Progression of a CD4+/CD56+ blastic plasmacytoid DC neoplasm after initiation of extracorporeal photopheresis in an allogeneic transplant recipient. *BONE MARROW TRANSPL*, 46: 899-900.
9. Gerstel D, Wegwitz F, Jannasch K, Ludewig P, Scheike K, Alves F, Beauchemin N, Deppert W, Wagener C, Horst AK (2011) CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. *ONCOGENE*, 30: 4275-88.
10. Grass S, Preuss KD, Thome S, Weisenburger DD, Witt V, Lynch J, Zettl F, Trümper L, Fadle N, Regitz E, Lynch H, Pfreundschuh M (2011) Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM. *BLOOD*, 118: 635-7.
11. Grgic A, Nestle U, Scheidhauer K, Puskas C, Ballek E, Hohloch K, Schubert J, König J, Pinkert J, Truemper L, Hellwig D, Kirsch CM (2011) Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma. *NUKLEARMED-NUCL MED*, 50: 39-47.
12. Haase D (2011) Genetic and molecular basis in myeloid neoplasias in relation with treatment. *HAEMATOL-HEMATOL J*, 96 (Extra1): 210-219.
13. Herrmann MKA, Bloch E, Overbeck T, Koerber W, Wolff HA, Hille A, Vorwerk H, Hess CF, Müller M, Christiansen H, Pradier O (2011) Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC--treatment results after long-term follow-up and literature overview. *CANCER RADIOTHER*, 15: 81-8.
14. Heuer JF, Gruschka D, Crozier TA, Bleckmann A, Plock E, Moerer O, Quintel M, Roessler M (2011) Accuracy of prehospital diagnoses by emergency physicians: comparison with discharge diagnosis. *EUR J EMERG MED*, 78: 315-321.
15. Hohloch K, Zinzani PL, Linkesch W, Jurczak W, Deptala A, Lorsche M, Windemuth-Kieselbach C, Wulf GG, Truemper LH (2011) Radioimmunotherapy with (90)Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. *BONE MARROW TRANSPL*, 46: 901-3.
16. Hohloch K, Delaloye AB, Windemuth-Kieselbach C, Gómez-Codina J, Linkesch W, Jurczak W, Cacchione R, Suh C, Zinzani PL, Trümper L (2011) Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network. *J NUCL MED*, 52: 1354-60.
17. Hohloch K, Sahlmann CO, Lakhani VJ, Wulf G, Glaß B, Hasenkamp J, Meller J, Riggert J, Trümper L, Griesinger F (2011) Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue. *ANN HEMATOL*, 90: 1307-15.
18. Jung AG, Horny HP, Sotlar K, Overbeck T, Schön MP, Lippert U (2011) Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. *J AM ACAD DERMATOL*, 65: 224-6.
19. Kendziorra E, Ahlborn K, Spitzner M, Rave-Fränk M, Emons G, Gaedcke J, Kramer F, Wolff HA, Becker H, Beissbarth T, Ebner R, Ghadimi BM, Pukrop T, Ried T, Grade M (2011) Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. *CARCINOGENESIS*, 32: 1824-31.

Abteilung "Haematologie u. Onkologie"

20. Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkötter E, Behme D, Schulz M, Schaffrinski M, Schindler S, Trümper L, Kramer F, Beissbarth T, Stadelmann C, Binder C, Pukrop T (2011) β -catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. *CARCINOGENESIS*, 32: 434-42.
21. Knösel M, Klein S, Bleckmann A, Engelke W (2011) Tongue position after deglutition in subjects with habitual open-mouth posture under different functional conditions. *ORTHOD CRANIOFAC RES*, 14: 181-8.
22. Knösel M, Jung K, Bleckmann A (2011) YouTube, dentistry, and dental education. *J DENT EDUC*, 75: 1558-68.
23. Knösel M, Klein S, Bleckmann A, Engelke W (2011) Coordination of Tongue Activity During Swallowing in Mouth-breathing Children. *DYSPHAGIA*, Epub: ahead of print.
24. Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *J CLIN ONCOL*, 29: 2709-16.
25. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespi T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz M?, Valencia A, Florensa L, Sanz GF, Haase D, Solé F (2011) Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. *LEUKEMIA*, 25: 110-20.
26. Mallo M, Luño E, Sanzo C, Cervera J, Haase D, Schanz J, García-Manero G, Del Cañizo C, Sanz GF, Solé F (2011) Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. *LEUKEMIA RES*, 35: 834-6.
27. Maneck M, Schrader A, Kube D, Spang R (2011) Genomic data integration using guided clustering. *BIOINFORMATICS*, 27: 2231-8.
28. Mathejczyk JE, Pauli J, Dullin C, Napp J, Tietze LF, Kessler H, Resch-Genger U, Alves F (2011) Spectroscopically Well-Characterized RGD Optical Probe as a Prerequisite for Lifetime-Gated Tumor Imaging. *MOL IMAGING*, 10: 469-80.
29. Missbach-Guentner J, Hunia J, Alves F (2011) Tumor blood vessel visualization. *INT J DEV BIOL*, 55: 535-46.
30. Mitteldorf C, Bertsch HP, Baumgart M, Haase D, Wulf G, Schön MP, Rosenwald A, Neumann C, Kaune KM (2011) Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q. *J EUR ACAD DERMATOL*, 25: 1225-9.
31. Napp J, Behnke T, Fischer L, Würth C, Wottawa M, Katschinski DM, Alves F, Resch-Genger U, Schäferling M (2011) Targeted luminescent near-infrared polymer-nanoprobes for in vivo imaging of tumor hypoxia. *ANAL CHEM*, 83: 9039-46.
32. Napp J, Mathejczyk JE, Alves F (2011) Optical imaging in vivo with a focus on paediatric disease: technical progress, current preclinical and clinical applications and future perspectives. *PEDIATR RADIOL*, 41: 161-75.
33. Neuhaus B, Bühren S, Böck B, Alves F, Vogel WF, Kiefer F (2011) Migration inhibition of mammary epithelial cells by Syk is blocked in the presence of DDR1 receptors. *CELL MOL LIFE SCI*, 68: 3757-70.
34. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. *LANCET ONCOL*, 12: 1013-22.
35. Raupach T, Münscher C, Beißbarth T, Burckhardt G, Pukrop T (2011) Towards outcome-based programme evaluation: using student comparative self-assessments to determine teaching effectiveness. *MED TEACH*, 33: e446-53.
36. Ripperger T, Tauscher M, Haase D, Griesinger F, Schlegelberger B, Steinemann D (2011) Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency. *HAEMATOL-HEMATOL J*, 96: 1892-4.

Abteilung "Haematologie u. Onkologie"

37. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, Burkhardt B, Trautmann H, Gesk S, Andrusiewicz M, Berger H, Fey M, Harder L, Hasenclever D, Hummel M, Loeffler M, Mahn F, Martin-Guerrero I, Pellissery S, Pott C, Pfreundschuh M, Reiter A, Richter J, Rosolowski M, Schwaenen C, Stein H, Trümper L, Wessendorf S, Spang R, Küppers R, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, German High-Grade Lymphoma Study Group, Berlin-Frankfurt-Münster-NHL trial group (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. *BLOOD*, 118: 139-47.
38. Sausbier U, Dullin C, Missbach-Guentner J, Kabagema C, Flockerzie K, Kuscher GM, Stuehmer W, Neuhuber W, Ruth P, Alves F, Sausbier M (2011) Osteopenia due to enhanced cathepsin K release by BK channel ablation in osteoclasts. *PLOS ONE*, 6: e21168.
39. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E (2011) Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. *J CLIN ONCOL*, 29: 1963-70.
40. Scholtysik R, Nagel I, Kreuz M, Vater I, Giefing M, Schwaenen C, Wessendorf S, Trümper L, Loeffler M, Siebert R, Küppers R (2011) Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. *INT J CANCER*, unbekannt: unbekannt.
41. Schrader A, Bentink S, Spang R, Lenze D, Hummel M, Kuo M, Arrand JR, Murray PG, Trümper L, Kube D, Vockerodt M (2011) High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. *INT J CANCER*, epub: ahead of print.
42. Schubert-Fritsche G, Kube D, Eckel R, Engel J (2011) Epidemiologie maligner Non-Hodgkin Lymphome. *Tumordiagn Ther*, 1: 9-14.
43. Schulz P, Fischer C, Detjen KM, Rieke S, Hilfenhaus G, von Marschall Z, Böhmig M, Koch I, Kehrberger J, Hauff P, Thierauch KH, Alves F, Wiedenmann B, Scholz A (2011) Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. *FASEB J*, 25: 3325-35.
44. Stangl S, Gehrman M, Dressel R, Alves F, Dullin C, Themelis G, Ntziachristos V, Staebelin E, Walch A, Winkelmann I, Multhoff G (2011) In vivo imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody. *J CELL MOL MED*, 15: 874-87.
45. Streit F, Binder L, Hafke A, Brandhorst G, Bräulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P (2011) Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. *THER DRUG MONIT*, 33: 632-43.
46. Twarock S, Freudenberger T, Poscher E, Dai G, Jannasch K, Dullin C, Alves F, Prenzel K, Knoefel WT, Stoecklein NH, Savani RC, Homey B, Fischer JW (2011) Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. *MOL CANCER*, 10: 30.
47. Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmüller J, Benöhr P (2011) Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. *PHARMACOGENOMICS*, 12: 1417-27.
48. Uhmann A, van den Brandt J, Dittmann K, Heß I, Dressel R, Binder C, Lühder F, Christiansen H, Fassnacht M, Bhandoola A, Wienands J, Reichardt HM, Hahn H (2011) T cell development critically depends on prethymic stromal patched expression. *J IMMUNOL*, 186: 3383-91.
49. Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG (2011) Down-regulation of BLIMP1 by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. *BLOOD*, 117: 5907-17.
50. Wolff HA, Daldrup B, Jung K, Overbeck T, Hennies S, Matthias C, Hess CF, Roedel RMW, Christiansen H (2011) High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. *RADIOLOGY*, 258: 864-71.

Buchbeiträge

1. Binder C (2011) The role of tumor-associated macrophages in malignant invasion. In: Lawrence T, Hagemann Th (Hg.) Springer Verlag, New York, 31-48.
2. Chapuy B, Hummel M, Trümper L (2011) Biologie Aggressiver Lymphome. In: N Schmitz (Hg.) UNI-MED Verlag, Bremen, 20-33.
3. Haase D, Ganster C, Steidl C, Bräulke F, Shirneshan K, Schanz J (2011) Cytogenetics in MDS. In: Judit Várkonyi (Hg.) Springer Verlag, Berlin, Heidelberg, 55-87.

Abteilung "Haematologie u. Onkologie"

4. Missbach-Guentner J, Dullin C, Klingner S, Oplesch E, Alves F, Schultz M (2011) Analyse des Schienbeinschaftes des "Jungen von Kayhausen" mittels hochauflösender Computertomographie. In: Both F, Fansa M, Jopp E, Schultz M, Püschel K (Hg.) Isensee-Verlag, Oldenburg, 103-112.
5. Missbach-Güntner J, Dullin C, Schirmer J, Alves F, Schultz M (2011) Analyse des Hautfragments der Moorleiche "Bareler Moor" mittels hochauflösender Computertomographie. In: Both F, Fansa M, Jopp E, Schultz M, Püschel K (Hg.) Isensee-Verlag, Oldenburg, 165-72.
6. Neumann S, Trümper L (2011) Non-Hodgkin Lymphoma. In: Ajithkumar, Barrett, Hatcher, Cook (Hg.) Oxford University Press, Oxford, 448-465.
7. Neumann S, Wulf G, Trümper L (2011) Periphere T-Zell-Lymphome. In: C. Buske, S. Mahlmann (Hg.) Deutscher Ärzte-Verlag, Köln, 161-181.

Medizinische Dissertationen

1. Drevs J, Dr. med., Selbsttoleranz von NK-Zellen. Dissertation Universität Göttingen 2011.
2. Hangen H, Dr. med., Expression von Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) in Blasten von Patienten mit akuter myeloischer Leukämie. Dissertation Universität Göttingen 2011.
3. Karim K, Dr. med., Brüche am MLL-Gen durch apoptotische Vorgänge im Zuge von Probenalterungen im Vergleich zu Brüchen im MLL-Gen bei t-AML. Dissertation Universität Göttingen 2011.
4. Riechel C, Dr. med., Nachweis zytogenetischer Aberrationen nach Chemotherapie zur diagnostischen Früherkennung therapieassoziiertes hämatologischer Neoplasien. Dissertation Universität Göttingen 2011.
5. Stenger I, Dr. med., Mitomycin/Cisplatin oder Mitomycin/Vinorelbin und Erythropoetin als Therapie bei vorbehandelten Patienten mit Rezidiv eines NSCLC innerhalb des Bestrahlungsfeldes. Dissertation Universität Göttingen 2011.
6. Stoller I, Dr. med., Zytokinrezeptorpolymorphismen bei Patienten mit T-Non-Hodgkin-Lymphomen. Dissertation Universität Göttingen 2011.

Zahnmedizinische Dissertationen

1. Dicke C, Dr. med., Die Bedeutung von Dishevelled in der Wnt-5a-induzierten Signaltransduktion. Dissertation Universität Göttingen 2011.
2. Hartmann J, Dr. med., Progenitorzeleigenschaften bei myelodysplastischen Syndromen (MDS) mit Eisenüberladung. Dissertation Universität Göttingen 2011.
3. Matthias K, Dr. med., Die Analyse der Rolle von STAT6 im klassischen Hodgkin-Lymphom. Dissertation Universität Göttingen 2011.

Naturwiss. u.a. nichtmed. Diss.

1. Chuang E, Dr. rer. nat., Effects of Wnt and different TLR stimulations in microglia-induced invasion of breast cancer cells. Dissertation Universität Göttingen 2011.
2. Mathejczyk E, Dr. rer. nat., Innovative NIR fluorescent probes for an improved tumor detection in vivo. Dissertation Universität Göttingen 2011.
3. Schrader A, Dr. rer. nat., Identification and functional characterisation of oncogenic pathway signatures in malignant Lymphoma. Dissertation Universität Göttingen 2011.

Diplomarbeiten

1. Hansch A, Dipl.-Biol., Generierung eines neuen Mausstammes für eine zeitliche und räumlich kontrollierte Überexpression von BCL9-2 im embryonalen und adulten Gewebe. Diplomarbeit Universität Göttingen 2011.

Masterarbeiten

1. Menck K (2011) Identification and further characterization of pro-invasive microparticles in macrophage-induced breast cancer invasion. Universität Göttingen, MSc.
2. Moses K (2011) Comparative Analysis of BAFF Receptors and Associated Signaling Pathways in Non-Hodgkin Lymphoma Cells. Universität Göttingen, MSc.